General

Fluocinolone acetonide intravitreal implant reduces macular edema through 36 months

A fluocinolone acetonide intravitreal implant (Fai) (Yutiq; EyePoint Pharmaceuticals) insert reduced rates of macular edema and improved visual acuity in eyes with noninfectious uveitis affecting the posterior segment (NIU-PS) through 36 months, according to a presentation at the 2020 ASRS Virtual Meeting. In this prospective, randomized, phase 3 clinical trial, patients...